// App-Quantinova.ai

6586.0 : Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.

Researchers

Presenter

  • Eoghan Ruadh Malone

Principal Investigators

  • Anna Spreafico

  • Ilan Weinreb

  • Sarah Jennings

  • Lindsay Carlsson

  • Ahmad Noori

  • Lisa Wang

  • Lillian L. Siu

  • Aaron Richard Hansen

Medical Centers

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Wharton Head and Neck Program, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Universtiy Health Network, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • erb-b2 receptor tyrosine kinase 2

  • Exportin 1

Drug/Treatment

  • Selinexor

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02069730

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved